Lichscheidt Emil Dariush, Harboe Zitta Barrella, Fischer Thea Kølsen, Larsen Carsten Schade
Infektionsmedicinsk Afdeling, Aarhus Universitetshospital.
Medicinsk Afdeling, Regionshospitalet Randers.
Ugeskr Laeger. 2024 Mar 11;186(11). doi: 10.61409/V12230800.
Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.
呼吸道合胞病毒（RSV）是一种常见的呼吸道病毒，可导致婴儿、患有合并症的老年人以及免疫功能低下的成年人出现相当高的发病率和死亡率。两种疫苗，Abrysvo和Arexvy，已被批准用于预防60岁及以上成年人的严重RSV感染。此外，Abrysvo被批准在孕期使用，以保护婴儿免受RSV相关的下呼吸道感染。目前，尚无关于使用这些疫苗的全国性建议，但在共同的临床决策中应考虑为严重RSV感染风险最高的老年人接种疫苗。
